Clinicians Push Earlier JAK Inhibitor Use in AD and Vitiligo
Fall Clinical Derm 2026 experts say JAK inhibitors should move earlier in AD and vitiligo care, before disease becomes chronic and pigment reserves are lost.
Topic
Jak Inhibitors
Topic
Jak Inhibitors
REZOLVE-AA Trial Reports Durable Hair Regrowth With Rezpegaldesleukin
REZOLVE-AA topline data show rezpegaldesleukin produces durable hair regrowth in alopecia areata, per Dermatology Times — a susta…
TRANQUILLO 2: Ritlecitinib Posts 21.86% F-VASI75 in Vitiligo
Ritlecitinib 100 mg drove a 21.86% F-VASI75 response at week 52 in the phase 3 TRANQUILLO 2 trial of nonsegmental vitiligo, again…
Pfizer Reports 'Promising Win' for Experimental Atopic Dermatitis Drug
Pfizer's experimental atopic dermatitis candidate produced what the company called a "promising win" in a finance.yahoo.com syndi…
LEO Pharma Brings Delgocitinib Cream Data to EADV 2026
LEO Pharma presented new delgocitinib cream data at EADV 2026, spanning real-world adult outcomes and new adolescent findings in…
REZOLVE-AA Trial Reports Durable Hair Regrowth With Rezpegaldesleukin
Rezpegaldesleukin delivered durable hair regrowth in the REZOLVE-AA alopecia areata trial, strengthening the case for selective I…
Journal Digest: Oral Minoxidil Consensus, JAK Imaging, RF Microneedling for Rosacea
Eighty-four of 127 items reached consensus in a 50-expert Delphi on pediatric oral minoxidil; a 60-week study shows RCM inflammat…
JAAD Study Examines Pediatric Enrollment in Alopecia Areata Trials
A cross-sectional analysis published October 8, 2026 in JAAD audits pediatric enrollment and demographic reporting across alopeci…
Upadacitinib Clears Refractory ARPC After Dupilumab Failure
Upadacitinib 15 mg daily cleared refractory ARPC in a stage 4 CKD patient after dupilumab triggered paradoxical worsening within…
Upadacitinib Shows Long-Term Utility Across Three Immune Skin Diseases
A Frontiers case report documents long-term upadacitinib therapy in one patient with atopic dermatitis, bullous pemphigoid and al…